Your Position: Home > Journal List > CHINA MEDICINE > Paper

Effect of vinpocetine on inflammation in rats with chronic obstructive pulmonary disease

( views:379, downloads:0 )
QU Bin-bin(Department of Respiratory,Second Affliated Hospital of Qingdao University Medical College,Qingdao 266042,China)
ZHANG Chun-ling(Department of Respiratory,Second Affliated Hospital of Qingdao University Medical College,Qingdao 266042,China)
Journal Title:
Volume 06, Issue 07, 2011
Key Word:
Pulmonary disease,chronic obstructive;Inflammation;Rats,Wistar;Vinpocefine

Abstract: Objective To observe the effect of vinpecetine on inflammatory factors and lung pathology of the rats with chronic obstructive pulmonary disease(COPD),and to investigate the therapeutic action of vinpecetine on COPD.Methods Totally 40 Wistar rats were randomly divided into the normal control group,the COPD model group and three viupocetine treated groups.The COPD rat model wag established by intratracheal instillation of lipepalysaceharide and exposure to cigarette smoke.The three intervention groups were intrapedtonealy injected with vinpecetine respectively at the dose of 1.25 mg/kg,2.5 mg/kg and 5 mg/kg before exposing to cigarette smoke.Pathologic changes of the lung tissue,interlukin(IL)-8 and tumor necrosis factor (TNF)-a levels in bronchial alveolarhvage fluid(BALF)and seruln,and CRP level in the serum were determined.Results The pathological changes in the COPD rat model were coincident with the changes in human.Compared with the COPD model group,the two groups treated with vinpecetine at the dose of 2.5 mg/kg and 5 mg/kg showed a significan t decrease in IL-8[(18.40 ±2.40)ng/L,(19.30±3.11)ng/L respectively vs(23.81±3.54)ng/L],TNF-a[(39.34±3.43)ng/L,(40.47±3.09)ns/L respectivelyvs (46.65±4.42)ng/L],and CRP[(4.28±0.22)mg/L,(4.35±0.26)mg/L respectively vs(4.69±0.19)mg/L]in serum.In the BALF of those the BALF of those two groups, the levers of Ⅱ-8[(20.09 4±2.88)ng/L,(21.03±2.21)ng/L]and TNF-a[(40.41±4.40)ng/L,(41.18 4±5.33)ng/L]were also significantly lower than those in the moder group[(25.02±2.92).g/L,(48.81±4.92)ng/L].The vinpocetine treated group at the dose of 1.25mg/kg ad no significant difference, compared with the COPD model group. Conclusions Vinpocetine can reduce the levels of inflammatory factors in BALF and the serum of the rats with COPD and decrease inflammation of the airway and lung tissue. Accordingly vinpecetine can inhibit the inflammation of the COPD rat model.

  • [1]Garrod R,Marshall J,Barley E,et al.The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease(COPD).Prim Care Respir J,2007,16(4):236-240.
  • [2]Jeon KI,Xu X,Aizawa T,et al.Vinpocetine inhibits NF-kappaBdependent inflammation via an IK-dependent but PDE-independent mechanism.Proc Nad Acad Sci U S A,2010,107(21):9795-9800.
  • [3]宋一平,崔德建,茅培英.慢性阻塞性肺病大鼠模型的建立及药物干预的影响.军医进修学院学报,2001,22(2):99-102.
  • [4]Pinto-Plata VM,Livnat G,Girish M,et al.Systemic cytokines,clinical and physidogical changesin patients hospitalizedfor exacerbation of COPD.Chest,2007,131(1):37-43.
  • [5]Eickmeier O,Huebner M,Herrmann E,et al.Sputum biomarker profiles in cystie fibrosis(CF)and chronic obstructive pulmonary disease(COPD)and association between pulmonary function.Cytokine,2010,SO(2):152-157.
  • [6]Garcia-Rio F,Mimvitlles M,Soriano JB,et al.Systemic inflammarion in chronic obstructive pulmonary disease:a populationbased study.Respir Res,2010,25(11):63.
  • [7]Thorleifsson SJ,Margretardottir OB,Gudmundsson G,et al.Chronic airflow obstruction and markers of systemie inflammation:results from the BOLD study in Iceland.Respir Med,2009,103(10):1548-1553.
  • [8]de Torres JP,Pinto-Plata V,Casanova C,et al.C-reactive protein leversand survivalin patients with moderateto very severe COPD.Chest,2008,133(6):1336-1343.
  • [9]张敏,刘华,孙华明.长春西汀合用脑蛋白水解物治疗动脉硬化性脑梗死患者的研究.现代中西医结合杂志,2010,19(5):526-528.
  • [10]张冬平,于燕.长春西汀治疗急性脑梗死疗效观察.实用药物与临床,2008,11(5):297-298.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615